等待开盘 05-12 09:30:00 美东时间
-0.050
-1.14%
PolyPid (NASDAQ:PYPD) is set to give its latest quarterly earnings report on We...
02-11 04:02
PolyPid secured $26.7 million through warrant exercises, extending its runway beyond FDA approval of D-PLEX₁₀₀. The product demonstrated significant reduction in surgical site infections in Phase 3 SHIELD II trial.
2025-06-16 23:20
PolyPid Ltd. announced positive results from its pivotal SHIELD II Phase 3 trial of D-PLEX 100, demonstrating statistically significant reductions in surgical site infections and meeting both primary and key secondary endpoints. The company plans to submit an NDA to the FDA in early 2026.
2025-06-09 11:30
The Company anticipates reporting top-line results by the end of the second quarter of 2025. If the Phase 3 data are positive, PolyPid expects to submit a New Drug Application ("NDA") to the U.S. Food and Drug
2025-03-11 19:57
05:03 PM EDT, 08/30/2024 (MT Newswires) -- PolyPid (PYPD) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to 3.9 million ordinary shares. The filing covers 2 million ordinary shares held by the selling shareholders, 1.7 million shares...
2024-08-31 05:03
PolyPid Files For Resale Of Up To 3.9M Ordinary Shares By Selling Shareholders
2024-08-31 04:04